ALLG HD10/ GHSG HD21 study open at Sir Charles Gairdner HospitalChan Cheah
The HD21 study, an Australiasian Leukaemia and Lymphoma Group collaboration with the German Hodgkin lymphoma stud group, is now open at SCGH.
This is the largest ever study to be performed in patients with advanced stage Hodgkin lymphoma, with a target recruitment of 1,600 patients in 10 countries. This is a randomized study comparing standard chemotherapy (BEACOPP escalated) to a new combination containing the antibody drug brentuximab vedotin (BreCADD). The question is whether this improves outcomes and reduces side effects in treatment-naive patients with stage IIB – IV Hodgkin lymphoma.
For more information, visit https://www.bloodcancerwa.org.au/trial/hd10hd21-beacon/
or ask your Haematologist